Natixis’s AMAG Pharmaceuticals AMAG Stock Holding History

Natixis’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-32,466	Closed	-$1.13M	–	1054
2016 Q4	$1.13M	Buy	+32,466	New	+$970K	0.01%	440

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Natixis's AMAG Position: Q1 2017 in Review

Natixis sold out of AMAG Pharmaceuticals (AMAG) in Q1 2017, closing a stake of 32,466 shares — an estimated $1.13M sold.

Natixis first reported a position in AMAG in Q4 2016 and held it in 1 quarter. The position peaked at $1.13M in Q4 2016. 185 funds tracked by Wall St. Rank hold AMAG as of Q1 2017.

Natixis reported no remaining AMAG Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Natixis sold 32,466 AMAG Pharmaceuticals shares in Q1 2017, an estimated $1.13M.
Natixis first reported a position in AMAG Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Natixis's AMAG Pharmaceuticals position peaked at $1.13M in Q4 2016.
185 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2017.

Based on Natixis's 13F filing for Q1 2017, filed 15 May 2017.